News

Currently awaiting transparency on tax incentives, the GSK Consumer team has already picked out one location each in Nellore and Chittoor for the new facility, which will produce

The latest approval will pave for Cbris Lifesciences to improve capacities to develop in the regulated markets, mainly the European Union. By the end of June, Cbris had

As part of the move, hydrocodone combination products (HCP) have now been moved to the more-restrictive Schedule II substances from Schedule III. The new rule will go live

Based on data from the global AMPLIFY and AMPLIFY-EXT studies, Eliquis was also cleared for the reduction in the risk of recurrent DVT and PE following initial therapy.

Paradigm will use its advanced molecular capabilities to characterize patient tissue samples from clinical trials to better predict which patients may be sensitive or resistant to TESARO’s TSR-011.

PGTC is one of the most severe forms of generalized seizures, accounting for approximately 60% of generalized epilepsy and approximately 20% of all epilepsy cases. This application was

Under the agreement, the company has purchased ANDAs for 0.5mg, 1mg and 2mg Estradiol Tablets, and 5mg Selegiline Hydrochloride Capsules. The seller’s identity and the financial terms of

Discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland, GBR 1302 is a HER2xCD3 bispecific antibody based on the company’s BEAT antibody technology

The three-year research is aimed at leveraging complementary strengths, expertise and assets to certify and progress new research targets and molecules into clinical development. Spanning from target selection